Back to Journals » Blood and Lymphatic Cancer: Targets and Therapy » Volume 1 » default
Blood and Lymphatic Cancer: Targets and Therapy
ISSN: 1179-9889
- View all (103)
- Volume 14, 2024 (2)
- Volume 13, 2023 (7)
- Volume 12, 2022 (12)
- Volume 11, 2021 (6)
- Volume 10, 2020 (2)
- Volume 9, 2019 (7)
- Volume 8, 2018 (7)
- Volume 7, 2017 (8)
- Volume 6, 2016 (5)
- Volume 5, 2015 (11)
- Volume 4, 2014 (13)
- Volume 3, 2013 (6)
- Volume 2, 2012 (12)
- Volume 1, 2011 (5)
Archive: Volume 1, 2011
Reduced intensity treatment in early-stage Hodgkin’s lymphoma
Prodduturi P, Armitage JO
Blood and Lymphatic Cancer: Targets and Therapy 2011, 1:23-31
Published Date: 25 November 2011
mTOR inhibitor in the treatment of Hodgkin’s lymphoma: a case report
Ibeas P, Cantos B, Provencio M.
Blood and Lymphatic Cancer: Targets and Therapy 2011, 1:19-22
Published Date: 8 November 2011
Leptomeningeal myelomatosis in previously treated high-risk kappa light chain multiple myeloma: case report and literature review
Ohanian M, Alaly J, Samuel S, Cable C, Halka K
Blood and Lymphatic Cancer: Targets and Therapy 2011, 1:9-18
Published Date: 28 September 2011
Mantle cell leukemia as a cause of leukostasis
Smith D, Cable C, Chisholm C, Linz W, Koss W, Dobin S, Rappaport E
Blood and Lymphatic Cancer: Targets and Therapy 2011, 1:5-8
Published Date: 28 April 2011
A new era in blood and lymphatic cancer biology and therapy
David Dingli
Blood and Lymphatic Cancer: Targets and Therapy 2011, 1:1-3
Published Date: 8 March 2011